Inspira Technologies Oxy B.H.N. Ltd. (IINNW) Stock Analysis

Company Overview

Inspira Technologies Oxy B.H.N. Ltd. operates as a specialty medical device company focused on the research, development, manufacturing, and marketing of proprietary life support technologies designed for the treatment of acute respiratory failure in Israel. The company specifically offers the INSPIRA ART100, a life support system utilized in critical care procedures, highlighting its specialization in advanced medical equipment rather than general consumer goods. Although the specific sector and industry classifications are not publicly disclosed in the available data, the company's operational focus on acute respiratory failure places it within the healthcare technology domain, a sector characterized by high regulatory standards and specialized demand. The company's scale is defined by a market capitalization that is currently unlisted, an annual revenue of $289,000, and an employee count that is not specified in the provided records. These financial metrics indicate that Inspira Technologies Oxy B.H.N. Ltd. functions as a small-cap entity with limited revenue generation relative to typical publicly traded peers, suggesting a niche market position where revenue figures do not yet reflect significant scale or widespread commercial adoption.

Financial Health

The company reported a trailing twelve-month revenue of $289,000 alongside a net income of $-13,220,000 and an EBITDA of $-13,473,000. The substantial gap between the minimal revenue of $289,000 and the significant net loss of $13,220,000 reveals a highly leveraged cost structure where operating expenses and cost of goods sold far exceed sales volume, likely due to heavy investment in research and development or high manufacturing costs relative to current sales. Free cash flow stands at $-9,243,375, indicating that the company is burning cash rapidly, which severely limits its financial flexibility to fund operations without external capital injections or dilution. Margin analysis shows a gross margin of 0.7%, an operating margin of -4713.8%, and a profit margin of 0.0%, each figure pointing to severe inefficiency; the negative operating and profit margins confirm that the company is unable to cover its operating costs or generate any profit from its sales. On the balance sheet, the company holds $3.16M in cash against $480,000 in debt, while the debt-to-equity ratio is recorded at 20.66, suggesting a highly leveraged position where debt obligations are substantial relative to equity, though the cash balance provides a temporary buffer. The current ratio is 1.56, which indicates that the company possesses sufficient current assets to cover its short-term liabilities, although the high leverage and negative cash flow cast doubt on the sustainability of this liquidity position. Return on equity is -397.9% and return on assets is -127.0%, metrics that reveal management is currently destroying value rather than generating returns for shareholders or efficiently utilizing assets to produce income.

Valuation Assessment

The trailing P/E ratio and forward P/E ratio are both unlisted in the available data, making it impossible to calculate a difference between them or infer an expected earnings trajectory based on these specific valuation multiples. The price-to-book ratio is 1.49, which indicates that the market values the company at a premium of 49% over its book value, a metric that can be misleading for loss-making companies where book value may not accurately reflect enterprise value. Alternative valuation metrics such as the price-to-sales ratio and EV/EBITDA are also unlisted, suggesting that traditional valuation models based on earnings or sales multiples are not applicable due to the company's negative earnings and lack of standardized market data. The 52-week high is $0.80 and the 52-week low is $0.05, and without a specific current price provided in the facts, the exact percentage deviation from this range cannot be calculated, but the wide spread implies significant price volatility. The beta value is unlisted, so a direct comparison to the broader market's volatility cannot be made using the provided data, though the wide trading range between $0.05 and $0.80 suggests high price instability independent of market beta.

Growth & Income

Revenue growth year-over-year and earnings growth year-over-year are both unlisted in the available facts, preventing a direct comparison of whether earnings are growing faster or slower than revenue. Since the company reports a net loss of $-13,220,000 and a negative free cash flow, it does not pay dividends; therefore, the dividend yield and payout ratio are not applicable, and the company effectively reinvests its limited resources or seeks external funding to sustain operations rather than distributing income to shareholders. The overall growth and income profile is characterized by a lack of historical growth data and an absence of dividend income, reflecting a stage of development where the company prioritizes operational survival and product development over shareholder returns or revenue expansion.